Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer|Bone Metastases in Subjects With Advanced Breast Cancer|Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Interventions: DRUG: amg 162
Sponsor: Amgen